Literature DB >> 16461069

Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature.

Fabian A Mendoza1, Carol M Artlett, Nora Sandorfi, Kevin Latinis, Sonsoles Piera-Velazquez, Sergio A Jimenez.   

Abstract

OBJECTIVES: To review the clinical and laboratory features of 12 cases of nephrogenic fibrosing dermopathy (NFD) studied at our institution and of 70 previously described cases in the literature.
METHODS: Clinical evaluation and laboratory studies of 12 patients with NFD associated with chronic hemodialysis or peritoneal dialysis for end-stage renal disease and a review of 23 previous publications describing 70 patients with this disease.
RESULTS: Eleven patients undergoing chronic hemodialysis and 1 patient undergoing chronic peritoneal dialysis for end-stage renal failure developed a severe and progressive cutaneous fibrotic process with woody induration of legs, thighs, hands, and forearms, and severe loss of motion and flexion contractures in multiple joints. Several patients displayed systemic involvement including fibrosis of muscles, myocardium, and lungs and marked elevations of the erythrocyte sedimentation rate and/or C-reactive protein. Three patients died within 2 years of symptom onset. A review of previously published reports of this disorder confirmed the presence of systemic involvement and a poor prognosis with a high mortality rate.
CONCLUSIONS: NFD is a severe and usually progressive systemic fibrotic disease affecting the dermis, subcutaneous fascia, and striated muscles. It also appears that the disease can cause fibrosis of lungs, myocardium, and other organs.

Entities:  

Mesh:

Year:  2006        PMID: 16461069      PMCID: PMC1434722          DOI: 10.1016/j.semarthrit.2005.08.002

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  29 in total

1.  Presence of CD45RO+ CD34+ cells with collagen synthesis activity in nephrogenic fibrosing dermopathy: a new pathogenic hypothesis.

Authors:  N Ortonne; D Lipsker; F Chantrel; N Boehm; E Grosshans; B Cribier
Journal:  Br J Dermatol       Date:  2004-05       Impact factor: 9.302

Review 2.  TGF-beta1 regulation of dendritic cells.

Authors:  H Strobl; W Knapp
Journal:  Microbes Infect       Date:  1999-12       Impact factor: 2.700

3.  Scleromyxoedema-like cutaneous diseases in renal-dialysis patients.

Authors:  S E Cowper; H S Robin; S M Steinberg; L D Su; S Gupta; P E LeBoit
Journal:  Lancet       Date:  2000-09-16       Impact factor: 79.321

4.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin.

Authors:  Sergio A Jiménez; Carol M Artlett; Nora Sandorfi; Chris Derk; Kevin Latinis; Heloisa Sawaya; Richard Haddad; Joseph C Shanahan
Journal:  Arthritis Rheum       Date:  2004-08

5.  Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy).

Authors:  Joshua M Levine; Robert A Taylor; Lauren B Elman; Shawn J Bird; Ehud Lavi; Ethan D Stolzenberg; Michael L McGarvey; Arthur K Asbury; Sergio A Jimenez
Journal:  Muscle Nerve       Date:  2004-11       Impact factor: 3.217

6.  Nephrogenic fibrosing dermopathy.

Authors:  T Gambichler; V Paech; A Kreuter; M Wilmert; P Altmeyer; M Stücker
Journal:  Clin Exp Dermatol       Date:  2004-05       Impact factor: 3.470

7.  Nephrogenic fibrosing dermopathy treated with extracorporeal photopheresis.

Authors:  Severin Läuchli; Claudia Zortea-Caflisch; Frank O Nestle; Günter Burg; Werner Kempf
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

8.  Expression of transforming growth factor type beta on human epidermal dendritic cells.

Authors:  M S Gruschwitz; O P Hornstein
Journal:  J Invest Dermatol       Date:  1992-07       Impact factor: 8.551

9.  Nephrogenic fibrosing dermopathy in a renal transplant recipient with tubulointerstitial nephritis and uveitis.

Authors:  Conrad Hauser; Gürkan Kaya; Carlo Chizzolini
Journal:  Dermatology       Date:  2004       Impact factor: 5.366

10.  Nephrogenic fibrosing dermopathy in pediatric patients.

Authors:  Sima M Jain; Stanton Wesson; Ashraf Hassanein; Erica Canova; Miranda Hoy; Robert S Fennell; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2004-02-10       Impact factor: 3.714

View more
  63 in total

1.  Proteomic analysis identification of a pattern of shared alterations in the secretome of dermal fibroblasts from systemic sclerosis and nephrogenic systemic fibrosis.

Authors:  Francesco Del Galdo; M Alexander Shaw; Sergio A Jimenez
Journal:  Am J Pathol       Date:  2010-08-19       Impact factor: 4.307

2.  Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis.

Authors:  Bruce L Riser; Narasimharao Bhagavathula; Patricia Perone; Kendra Garchow; Yiru Xu; Gary J Fisher; Feridoon Najmabadi; Durga Attili; James Varani
Journal:  J Cell Commun Signal       Date:  2012-05-31       Impact factor: 5.782

3.  Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis.

Authors:  Peter J Wermuth; Sergio A Jimenez
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

Review 4.  Dendritic cells: novel players in fibrosis and scleroderma.

Authors:  Theresa T Lu
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 5.  [Laboratory diagnostics for systemic sclerosis].

Authors:  R Mierau; A Roers; E Genth
Journal:  Z Rheumatol       Date:  2007-05       Impact factor: 1.372

Review 6.  Cutaneous Manifestations of Scleroderma and Scleroderma-Like Disorders: a Comprehensive Review.

Authors:  Caterina Ferreli; Giulia Gasparini; Aurora Parodi; Emanuele Cozzani; Franco Rongioletti; Laura Atzori
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

Review 7.  Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.

Authors:  Kerry A Layne; Paul I Dargan; John R H Archer; David M Wood
Journal:  Br J Clin Pharmacol       Date:  2018-08-17       Impact factor: 4.335

8.  [Nephrogenic systemic fibrosis].

Authors:  W Samtleben
Journal:  Radiologe       Date:  2007-09       Impact factor: 0.635

9.  Molecular ablation of transforming growth factor beta signaling pathways by tyrosine kinase inhibition: the coming of a promising new era in the treatment of tissue fibrosis.

Authors:  Joel Rosenbloom; Sergio A Jiménez
Journal:  Arthritis Rheum       Date:  2008-08

10.  Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease.

Authors:  Josef A Schroeder; Christian Weingart; Brigitte Coras; Ingrid Hausser; Stephan Reinhold; Matthias Mack; Volker Seybold; Thomas Vogt; Bernhard Banas; Ferdinand Hofstaedter; Bernhard K Krämer
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-02       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.